Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Operating Leases (2018 - 2023)

Historic Operating Leases for Ascendis Pharma A (ASND) over the last 6 years, with Q4 2023 value amounting to $91.0 million.

  • Ascendis Pharma A's Operating Leases fell 648.0% to $91.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $91.0 million, marking a year-over-year decrease of 648.0%. This contributed to the annual value of $91.0 million for FY2023, which is 648.0% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Operating Leases of $91.0 million as of Q4 2023, which was down 648.0% from $98.1 million recorded in Q3 2023.
  • Ascendis Pharma A's Operating Leases' 5-year high stood at $120.1 million during Q4 2021, with a 5-year trough of $15.0 million in Q1 2019.
  • Moreover, its 5-year median value for Operating Leases was $91.0 million (2023), whereas its average is $71.0 million.
  • Per our database at Business Quant, Ascendis Pharma A's Operating Leases skyrocketed by 25793.27% in 2021 and then tumbled by 1893.92% in 2022.
  • Ascendis Pharma A's Operating Leases (Quarter) stood at $40.5 million in 2019, then surged by 150.37% to $101.5 million in 2020, then grew by 18.32% to $120.1 million in 2021, then decreased by 18.94% to $97.3 million in 2022, then decreased by 6.48% to $91.0 million in 2023.
  • Its last three reported values are $91.0 million in Q4 2023, $98.1 million for Q3 2023, and $97.3 million during Q4 2022.